MPharma 's hard lessons scaling mPharma
A clear-eyed look at whether $a checkout SDK can $build for the informal economy.
MPharma 's hard lessons scaling mPharma
- How Uganda's market shapes the outcome.
- The real cost behind the pre-seed.
- What to watch next as the story develops.
A clear-eyed look at whether $a checkout SDK can $build for the informal economy.
- How Uganda's market shapes the outcome.
- The real cost behind the pre-seed.
- What to watch next as the story develops.
For anyone building in founder stories, the useful question is where this changes your costs, distribution or competition — and how soon you act on it.
AI-generated summary. It can miss nuance — read the full story above for the complete picture.
In Lusaka, the story of mPharma is becoming a case study in what it takes to build for the informal economy.
Backers including Partech Africa are wagering that a checkout SDK can win where global players have stalled.
Why it matters
The founders who win here treat discipline as a feature, not a phase.
Strip away the hype and you're left with a practical question about retention that every operator faces.
If it works, the playbook travels — to Ethiopia and beyond.
What to watch next
- Whether mPharma can hold margins while it chases profitability.
- Which rivals move first, and how global players counter.
- Whether the pre-seed buys enough runway to reach the next milestone.
For now, mPharma has bought itself time — and a story worth studying.
